
TOCA
Healthcare · Biotechnology · $2.0M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2020
EPS trend, 90 days to now · 0.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Apr 23, 2020 | Time not confirmed | -0.44 | -0.43 | +2.3% |
| Feb 28, 2020 | Time not confirmed | -0.57 | -0.50 | +12.3% |
| Nov 13, 2019 | Time not confirmed | -0.70 | -0.78 | -11.4% |
| Aug 9, 2019 | Time not confirmed | -0.76 | -0.72 | +5.3% |
| May 8, 2019 | Time not confirmed | -1.01 | -0.74 | +26.7% |
| Feb 27, 2019 | Time not confirmed | -10.26 | -14.40 | -40.4% |
| Nov 8, 2018 | Time not confirmed | -6.75 | -0.30 | +95.6% |
| Aug 7, 2018 | Time not confirmed | -8.90 | -12.15 | -36.5% |
| May 10, 2018 | Time not confirmed | -0.63 | -0.65 | -2.7% |
| Mar 8, 2018 | Time not confirmed | -0.62 | -0.55 | +11.3% |
Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca…